Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Attachment |
| Title | 24456794 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/24456794 |
| Accessed | 2018/05/23 - 14:04:46 |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de